The Global Immunology Market, by Drug Class (Monoclonal Antibody (mAb), Fusion Proteins, Immunosuppressants, Polyclonal Antibody (pAb), and Others), by Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America), is estimated to be valued at US$ 91,850 Million in 2021 and is projected to exhibit a CAGR of 8% during the forecast period (2021-2028)
As the number of successful clinical trials grows, so does the demand for biological pharmaceuticals, prompting various companies to invest in research and development to create biosimilars, which are a less expensive and more effective version of biological drugs. Therefore, the increasing demand for such products is expected to favor the global immunology market growth during the forecast period. For instance, Sandoz Canada launched Hyrimoz, an adalimumab (HUMIRA) biosimilar, in February 2021; the medicine has been approved and is effective in treating autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, adult Crohn's disease, and adult uveitis, among others.
Global Immunology Market– Impact of Coronavirus (COVID-19) Pandemic
COVID-19 pandemic has affected various industries globally. The players operating in the global Immunology market are facing major challenges on various fronts due to the COVID-19 pandemic. COVID-19 disease has affected the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Although for majority of market players the COVID-19 outbreak had a minimal impact on sales generated by immunological drugs; owing to an improved supply chain management, enhanced R&D capability, and an increased investment in manufacturing management & quality control. For instance in 2020, AbbVie Inc. reported an increase of 13.2% in the sales generated from the drugs as compared to in 2019. However, because to the COVID-19 pandemic, a few market participants saw a drop in revenues from immunology-related medications.
Browse 35 Market Data Tables and 36 Figures spread through 179 Pages and in-depth TOC on “Global Immunology Market, by Drug Class (Monoclonal Antibody (mAb), Fusion Proteins, Immunosuppressants, Polyclonal Antibody (pAb), and Others), by Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)- Forecast to 2028”
To know the latest trends and insights prevalent in Global Immunology Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/immunology-market-4594
Increasing acquisitions and collaboration among key players is expected to propel the growth of the global immunology market over the forecast period. For instance, Momenta Pharmaceuticals, Inc., a firm that discovers innovative medicines for immune-mediated disease, was acquired by Johnson & Johnson in August 2020. The Janssen Pharmaceutical Companies of Johnson & Johnson will be able to broaden their leadership in immune-mediated diseases and accelerate growth by expanding into autoantibody-driven disease as a result of this acquisition.
Key Takeaways of the Global Immunology Market:
- The global immunology market is expected to exhibit a CAGR of 8% during the forecast period, owing to the high prevalence of autoimmune conditions. According to the British Society for Immunology, an estimated 400,000 persons in the United Kingdom had rheumatoid arthritis in 2018, and an estimated 4 million people had an autoimmune disease.
- Among drug class, Monoclonal Antibody (mAb) segment is expected to dominate the immunology market owing to the established clinical efficiency of monoclonal antibodies such as adalimumab, rituximab, and the treatment of rare and chronic conditions as well as autoimmune diseases. For instance, STELARA (Ustekinumab), a human IgG1k monoclonal antibody developed by Janssen Global Services, LLC, was authorised by the US FDA in July 2020 to treat children patients with moderate to severe plaque psoriasis.
- Major players operating in the global Immunology market include AbbVie Inc., Janssen Global Services, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Novartis, Astellas, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., UCB SA, and Allergan plc.
